In the past 12 months, Intel (INTC) has surprisingly outperformed every major competitor — including NVIDIA, AMD, and TSMC. This is somewhat counterintuitive, given that Intel has long been viewed as the “sick man” of the semiconductor industry.

Source: TradingView
The rally has been supported by several key factors:
US Government Backing: The United States has effectively positioned Intel as its “National Champion.” The government took a 9.9% stake in the company for $8.9 billion, sending a strong signal that Intel is considered “too big to fail” despite its heavy debt load and operational challenges.
New Leadership: Hope has been reignited under new CEO Lip-Bu Tan, who took over last year. He has focused on streamlining operations and accelerating progress on the critical 18A and 14A process nodes.
Strategic Partnerships:
· The Terafab project with Elon Musk’s companies
· Collaboration with NVIDIA to package CPUs and integrate them with NVIDIA GPUs
· Deals with major hyperscalers (Amazon and Microsoft) looking to diversify their supply away from TSMC.
Most importantly, there is a rising demand for CPUs driven by the growth of agentic AI.
Metric | Consensus Estimate (Q1 2026) | Intel Official Guidance | Q1 2025 Actual | YoY Change |
Revenue | $12.52 Billion | $11.7B – $12.7B | $12.67 Billion | -1.18% |
Non-GAAP EPS | $0.01 | ~$0.00 (Breakeven) | $0.13 | -92.31% |
Gross Margin | 34.50% | 34.5% (Non-GAAP) | 37.78% | -3 pp |
Looking at these numbers, the growth and margin profile looks quite underwhelming — especially when compared to the explosive results from NVIDIA, AMD, and TSMC. This raises an important question: Is the positive market sentiment around Intel running significantly ahead of its fundamentals? In other words, are investors “turning on the stove before catching the fish”?
Intel’s business remains heavily concentrated in two core segments:
Other business lines are relatively minor and are not expected to be meaningful contributors in the near future.
Intel’s revenue growth continues to trail AMD for several structural reasons:
As a result, analysts do not expect Intel to return to meaningful revenue growth until 2027–2028, when better yields, improved supply, and a larger contribution from the foundry business (through Terafab or other major third-party customers) finally kick in.
Intel’s gross margin has fallen dramatically from historical levels above 60% to around 35% today.

Source: Macrotrends
A return to those peak levels looks highly improbable. In the past, Intel enjoyed overwhelming market dominance, strong pricing power, and efficient fabs. Today, it faces intense competition, low production yields, massive capital expenditure requirements, and heavy depreciation charges.
Even matching AMD’s roughly 55% gross margins over the long term seems unrealistic. AMD benefits from a much higher proportion of high-margin GPUs (30–35% of revenue in Q4 2025 versus less than 5% for Intel). GPUs command better pricing due to their semi-oligopolistic market structure and strong software ecosystems (CUDA for NVIDIA, ROCm for AMD), while CPUs have become more commoditized.
Additionally, AMD’s fabless model results in much lower depreciation (only 8–9% of revenue) compared to Intel’s ~21%. Even if Intel’s foundry business scales up, it is unlikely to reach TSMC’s 60%+ gross margins due to differences in experience, scale, and yields. Intel’s planned CapEx of $17–18 billion is spread across both products and foundry, while TSMC is expected to spend $52–56 billion — almost entirely focused on its core foundry operations.
This gap raises doubts about Intel’s ability to catch up technologically.
Not only this, Intel is also taking a significant first-mover risk by adopting High-NA EUV lithography, in contrast to TSMC’s more conservative Low-NA approach. If successful, this could allow Intel to leapfrog TSMC by 2027–2028 with a simpler and faster path to 1.4nm chips. However, being the pioneer also means confronting all the early operational challenges without the benefit of prior experience.
While the announced partnerships (Terafab, NVIDIA collaboration, hyperscaler deals) have generated excitement, most still lack clear revenue visibility. The financial impact of Terafab remains too early to quantify, and Intel’s exact role in NVIDIA’s Vera Rubin platform is still unclear.
At $20–$30 per share, Intel was undeniably cheap. At current levels of $60 and above, however, the valuation demands far more visible execution success. Much of the positive news — government backing, new leadership, and partnerships — already appears priced in. The underlying challenges remain - sluggish growth, compressed margins, operational risks around yields, and structural disadvantages including limited pricing power and an inefficient foundry model.
The bull case relies heavily on a successful turnaround, but meaningful proof is still pending.